OPR - Delayed Quote • USD RAPT Oct 2024 5.000 call (RAPT241018C00005000) Follow 4.0000 0.0000 (0.00%) At close: April 25 at 3:08 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for RAPT241018C00005000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: RAPT RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients 3 Biotech Stocks to Dump Before They Go to Zero What Makes RAPT Therapeutics (RAPT) an Investment Choice? Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting Insider Buyers Lose Additional US$63k As RAPT Therapeutics Dips To US$236m Rapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Tests RAPT Therapeutics Stock Is Down 63%. FDA Halts 2 Studies After Liver Failure. UPDATE 1-FDA puts on hold two Rapt Therapeutics mid-stage drug trials RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon FDA puts hold on Rapt trials of drug for eczema, asthma
